Celcuity Doses First Patient in Phase 3 Viktoria-2 Trial of Gedatolisib
Celcuity Inc. has initiated VIKTORIA-2, a Phase 3 clinical trial investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant...
Zoldonrasib: Breakthrough in G12D-Selective RAS(ON) Inhibition
Revolution Medicines announced the publication of research in •Science• detailing the discovery and development of zoldonrasib, a covalent inhibitor...
Unicycive Therapeutics Announces Positive Oxylanthanum Carbonate Trial Data
Unicycive Therapeutics announced positive results from a Phase 2 trial of its investigational phosphate binder, oxylanthanum carbonate (OLC), for...
Alumis Enrolls Final Patient in Global Phase 2b Trial of Next-Gen Oral TYK2 Inhibitor for SLE
Alumis, a late-stage biopharmaceutical company, has completed patient enrollment for its Phase 2b LUMUS trial of ESK-001, an oral...
Vonaprument Shows Promising Results in Phase 3 Trial for Dry AMD
Annexon, Inc. has completed enrollment in its Phase 3 ARCHER II trial for vonaprument, a drug targeting dry age-related...
Quanta Announces Leadership Team & Clinical Progress
Quanta Therapeutics appointed Vanessa L. Jacoby as Chief Business Officer and Chief Financial Officer, bringing over 25 years of...
Alzamend Neuro 2025 Financial Results & Clinical Program Updates
Alzamend Neuro, a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, reported positive...
Novel Genetic Evidence Confirms ADH1 Prevalence & Underdiagnosis
An analysis of genetic and health data from over 700,000 individuals confirms previous estimates of Autosomal Dominant Hypocalcemia type...
Dr. Iwasaki Joins Spear Study on Long COVID Antibodies
Invivyd has appointed Dr. Akiko Iwasaki, a renowned immunobiologist from Yale School of Medicine, to its SPEAR Study Group....
Scancell’s Phase 2 Data Shows Improved Outcomes in Late-Stage Melanoma
Scancell Holdings plc announced positive Phase 2 SCOPE trial data for its SCIB1/iSCIB1+ Immunobody® DNA active immunotherapies combined with...